tetano
Editor, Senior Moderator
Cell Rep Med
. 2024 Feb 21:101433.
doi: 10.1016/j.xcrm.2024.101433. Online ahead of print. Adjuvanted nanoliposomes displaying six hemagglutinins and neuraminidases as an influenza virus vaccine
Zachary R Sia[SUP] 1 [/SUP], Jayishnu Roy[SUP] 1 [/SUP], Wei-Chiao Huang[SUP] 2 [/SUP], Yiting Song[SUP] 1 [/SUP], Shiqi Zhou[SUP] 1 [/SUP], Yuan Luo[SUP] 1 [/SUP], Qinzhe Li[SUP] 1 [/SUP], Dominic Arpin[SUP] 3 [/SUP], Hilliard L Kutscher[SUP] 4 [/SUP], Joaquin Ortega[SUP] 3 [/SUP], Bruce A Davidson[SUP] 5 [/SUP], Jonathan F Lovell[SUP] 6 [/SUP]
Affiliations
Inclusion of defined quantities of the two major surface proteins of influenza virus, hemagglutinin (HA) and neuraminidase (NA), could benefit seasonal influenza vaccines. Recombinant HA and NA multimeric proteins derived from three influenza serotypes, H1N1, H3N2, and type B, are surface displayed on nanoliposomes co-loaded with immunostimulatory adjuvants, generating "hexaplex" particles that are used to immunize mice. Protective immune responses to hexaplex liposomes involve functional antibody elicitation against each included antigen, comparable to vaccination with monovalent antigen particles. When compared to contemporary recombinant or adjuvanted influenza virus vaccines, hexaplex liposomes perform favorably in many areas, including antibody production, T cell activation, protection from lethal virus challenge, and protection following passive sera transfer. Based on these results, hexaplex liposomes warrant further investigation as an adjuvanted recombinant influenza vaccine formulation.
Keywords: adjuvant; antigen display; influenza virus; liposome; subunit vaccine.
. 2024 Feb 21:101433.
doi: 10.1016/j.xcrm.2024.101433. Online ahead of print. Adjuvanted nanoliposomes displaying six hemagglutinins and neuraminidases as an influenza virus vaccine
Zachary R Sia[SUP] 1 [/SUP], Jayishnu Roy[SUP] 1 [/SUP], Wei-Chiao Huang[SUP] 2 [/SUP], Yiting Song[SUP] 1 [/SUP], Shiqi Zhou[SUP] 1 [/SUP], Yuan Luo[SUP] 1 [/SUP], Qinzhe Li[SUP] 1 [/SUP], Dominic Arpin[SUP] 3 [/SUP], Hilliard L Kutscher[SUP] 4 [/SUP], Joaquin Ortega[SUP] 3 [/SUP], Bruce A Davidson[SUP] 5 [/SUP], Jonathan F Lovell[SUP] 6 [/SUP]
Affiliations
- PMID: 38401547
- DOI: 10.1016/j.xcrm.2024.101433
Inclusion of defined quantities of the two major surface proteins of influenza virus, hemagglutinin (HA) and neuraminidase (NA), could benefit seasonal influenza vaccines. Recombinant HA and NA multimeric proteins derived from three influenza serotypes, H1N1, H3N2, and type B, are surface displayed on nanoliposomes co-loaded with immunostimulatory adjuvants, generating "hexaplex" particles that are used to immunize mice. Protective immune responses to hexaplex liposomes involve functional antibody elicitation against each included antigen, comparable to vaccination with monovalent antigen particles. When compared to contemporary recombinant or adjuvanted influenza virus vaccines, hexaplex liposomes perform favorably in many areas, including antibody production, T cell activation, protection from lethal virus challenge, and protection following passive sera transfer. Based on these results, hexaplex liposomes warrant further investigation as an adjuvanted recombinant influenza vaccine formulation.
Keywords: adjuvant; antigen display; influenza virus; liposome; subunit vaccine.